Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06872866 · ClinicalTrials.gov registry record · Phase 1
The Objective of This Phase 1 Study is to Evaluate the Food Effect of 100 mg Hezkue Turbo® (ASP-001.1, Sildenafil) Under Fed Versus 100 mg of Hezkue Turbo® (ASP-001.1, Sildenafil) Under Fasted Conditions in Healthy Adult Male Subjects
A Phase 1 study of Erectile Dysfunction, sponsored by Aspargo Labs.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT06872866: Recruiting Phase 1 study of Erectile Dysfunction, sponsored by Aspargo Labs.
NCT06872866 is a Phase 1 study of Erectile Dysfunction that is actively recruiting participants, run by Aspargo Labs. The registered enrollment target is 12 participants, below the 231-participant average among 33 other Erectile Dysfunction trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06872866, a Phase 1 study of Erectile Dysfunction, is actively recruiting participants, sponsored by Aspargo Labs.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this phase 1 study is to evaluate the food effect of 100 mg Hezkue Turbo® (ASP-001.1, sildenafil) under fed versus 100 mg of Hezkue Turbo® (ASP-001.1, sildenafil) under fasted conditions in healthy adult male subjects
Primary Outcome
The PK profile of ASP-001.1 in healthy male subjects under fasted vs fed conditions. Calculation of maximum plasma concentration (Cmax) over the specified timeframe.
Conditions Studied
Interventions
- DRUG ASP-001.1
- DEVICE ASP-001.1
Study Locations (1)
New York
- Aspargo Labs - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2025-04-15 |
| Est. Completion | 2026-02-28 |
| Phase | Phase 1 |
What NCT06872866 shows while recruiting
NCT06872866 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 231-participant average among 33 other Erectile Dysfunction trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Erectile Dysfunction appearing as the primary indexed condition, and to 2 interventions - of which ASP-001.1 is the first listed.
NCT06872866 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06872866 about?
NCT06872866 is a clinical study titled "The Objective of This Phase 1 Study is to Evaluate the Food Effect of 100 mg Hezkue Turbo® (ASP-001.1, Sildenafil) Under Fed Versus 100 mg of Hezkue Turbo® (ASP-001.1, Sildenafil) Under Fasted Conditions in Healthy Adult Male Subjects". The objective of this phase 1 study is to evaluate the food effect of 100 mg Hezkue Turbo® (ASP-001.1, sildenafil) under fed versus 100 mg of Hezkue Turbo® (ASP-001.1, sildenafil) under fasted conditions in healthy adult male subjects
What is the current status of trial NCT06872866?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2025-04-15. Estimated completion is 2026-02-28.
What conditions does trial NCT06872866 study?
This clinical trial studies the following conditions: Erectile Dysfunction.
What interventions are being tested in trial NCT06872866?
The interventions under investigation include: ASP-001.1 (DRUG), ASP-001.1 (DEVICE).
Who is sponsoring clinical trial NCT06872866?
This trial is sponsored by Aspargo Labs, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06872866 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Erectile Dysfunction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06872866's enrollment target sits among peer trials
12 28th of 33 higher than 5 of 33 other Erectile Dysfunction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Erectile Dysfunction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Drug Interaction Study of Avanafil and Enalapril or Amlodipine
COMPLETED · Phase 1
-
PRP for the Treatment of Erectile Dysfunction (ED)
COMPLETED · Phase 1
-
Concurrent Low Intensity Shockwave Therapy on Collagenase Clostridium Histolyticum for Peyronie's Disease
RECRUITING · NA
-
Double-S: a Wearable Device for Erectile Dysfunction
RECRUITING · NA
-
Safety and Efficacy of the VERTICA® RF Device for the Treatment of ED
RECRUITING · NA
-
The Impact of Dietary Pattern on Erectile Function
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI